OUR EXECUTIVE TEAM
Spyridon “Spyros” Papapetropoulos, M.D., PhD
President & Chief Executive Officer
Spyros is an experienced biopharmaceutical executive, a recognized neuroscientist/neurologist, and change agent with a 25-year career focused on CNS disorders. He held various positions of increasing responsibility at CNS-focused start-up/small, medium specialty and large biopharma companies. Prior to joining Bionomics Ltd. he served as Chief Medical Officer of Vigil Neuroscience Inc, (NASDAQ: VIGL), as Chief Development Officer, and SVP, Head of Clinical Development at Acadia Pharmaceuticals Inc (NASDAQ: ACAD)., CEO at SwanBio Therapeutics, and EVP of Research & Development and Chief Medical Officer at Cavion Inc. Before Cavion, he held senior/executive positions at Biogen Inc., Allergan plc, Pfizer Inc., and Teva Pharmaceuticals Inc. Spyros has filed multiple INDs and has overseen a broad spectrum of CNS biopharmaceutical development programs (small molecules, biologics, gene therapy), leading to successful regulatory filings (20+ INDs and multiple NDAs/BLAs) and new product approvals and launches worldwide.
Mr Adrian Hinton BEc, FCA
Mr Hinton has had a long career with Deloitte (Adelaide) of over 43 years, retiring 1 July 2018 as Principle in the Audit and Assurance Group. He was responsible for managing the audit services to various Adelaide based public and private companies. His experience has given Mr Hinton a broad-based knowledge of contemporary accounting and audit issues inclusive of experience in working with a wide range of clients in different industries, from listed entities, private corporations to major subsidiaries of multinational listed companies, covering consumer, agriculture, retail, manufacturing, automotive, biopharmaceutical and resources sectors. Mr Hinton also has experience in preparing due diligence reviews, investigative accounting reports and the review of profit forecasts. Mr Hinton’s experience is currently benefited by being on the Boards of The Multiple Sclerosis Society of South Australia and Northern Territory, Carers Association of SA Inc, Australia PNG Alliance Group Pty Ltd and the Audit and Risk Committee of the University of South Australia. Mr Hinton also volunteers his time and skill set to aiding community groups both locally and internationally.
Ms Liz Doolin MSc
Vice President Clinical Development
Ms Doolin has over 25 years international experience in drug discovery, clinical and life sciences research. She joined Bionomics Limited in 2008 to lead the early clinical development program for BNC210, a small molecule with therapeutic potential for anxiety disorders, and trauma and stressor-related disorders including PTSD. Ms Doolin currently leads Bionomics’ clinical programs across central nervous system disorders and oncology, including three novel investigational drugs in Phase 1 and 2 clinical development. In addition to her extensive clinical research experience in Australia, Ms Doolin has a strong immunology and biotechnology research background, as well as biopharmaceutical development and GMP manufacturing experience, gained in New Zealand and the UK.
Julie Kerner PhD
SVP Business Operations
Julie is a biotech leader and enterprise thinker with 15+ years of drug development from early research through commercialization. Under her leadership, companies created portfolio and platform strategies, filed 10+ IND/CTAs, conducted proof of concept and Phase 3 trials, and launched multiple therapeutics. Most recently, Julie worked at Fulcrum Therapeutics and Aliada Therapeutics driving pipeline strategy and program leadership. Prior to that, she worked at AVROBIO, Wave Life Sciences, and Biogen working across R&D, Marketing, and early product planning. Before she joined industry, Julie earned a PhD in Neuroscience at Tufts Medical School and was a market analyst at Decision Resources, writing over 10 reports on neurodegeneration, psychology, and pain. Julie is committed to patient centricity and advocacy, sitting on the boards of Newton Wellesley Hospital, National Braille Press, and the US Neuroacanthocytosis advocacy, Inc.
Dr. Atul R. Mahableshwarkar MD
Dr. Mahableshwarkar is a seasoned Pharma Executive with strategic, developmental and regulatory experience in large global and small startup companies who has submitted INDs and NDAs leading to drug approvals. He is a Board Certified Psychiatrist, who graduated from the Armed Forces Medical College in India and completed a residency in Psychiatry and a fellowship in Neuropsychiatry from The Rosalind Franklin University of Health Sciences/The Chicago Medical School where he was an Associate Professor and Vice Chair of the Department of Psychiatry and Behavioral Sciences and also the Leader of the Mental Health Services Product Line at the North Chicago VAMC where he managed the mental health care to veterans at a hospital with over 800 inpatient beds. He’s had leadership roles as CMO and SVP/VP/Senior Director at small and large companies including Emalex Biosciences, BlackThorn Therapeutics, and Takeda. Dr. Mahableshwarkar has over 180 scientific publications, posters, and oral presentations with a track record of guiding programs to successful outcomes.
Mr. Tim Cunningham MBA
Chief Financial Officer
Mr. Cunningham has served as a Chief Financial Officer Consultant at Danforth, a strategic finance and operations firm with a focus on life sciences companies, since September 2020, where he provides chief financial officer consulting services to both public and private pharma and biotechnology companies. Prior to joining Danforth, Mr. Cunningham served as Chief Financial Officer at Organogenesis (NASDAQ:ORGO), where he took the company public and raised over US$250M in equity and debt financing to facilitate the company’s growth. He has held leadership positions with several different public and private companies over the course of his career, which began at KPMG in NY followed by PwC Boston. Mr. Cunningham holds an MBA from Boston University, a BS in Accounting from Boston College and is a CPA in the state of Florida.